Roberta L Mccaw Net Worth

The estimated Net Worth of Roberta L Mccaw is at least $2.1 Milión dollars as of 18 February 2015. Roberta Mccaw owns over 100,000 units of MiMedx Inc stock worth over $1,196,199 and over the last 15 years Roberta sold MDXG stock worth over $900,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Roberta Mccaw MDXG stock SEC Form 4 insiders trading

Roberta has made over 1 trades of the MiMedx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Roberta sold 100,000 units of MDXG stock worth $900,000 on 18 February 2015.

The largest trade Roberta's ever made was selling 100,000 units of MiMedx Inc stock on 18 February 2015 worth over $900,000. On average, Roberta trades about 50,000 units every 0 days since 2010. As of 18 February 2015 Roberta still owns at least 193,247 units of MiMedx Inc stock.

You can see the complete history of Roberta Mccaw stock trades at the bottom of the page.

What's Roberta Mccaw's mailing address?

Roberta's mailing address filed with the SEC is C/O MIMEDX GROUP, INC., 1775 WEST OAK COMMONS COURT, NE, MARIETTA, GA, 30062.

Insiders trading at MiMedx Inc

Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin a Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.

What does MiMedx Inc do?

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Complete history of Roberta Mccaw stock trades at MiMedx Inc

MiMedx Inc executives and stock owners

MiMedx Inc executives and other stock owners filed with the SEC include:

• Timothy Wright,
  Chief Executive Officer, Director
• Peter Carlson,
  Chief Financial Officer
• Timothy R. Wright,
  CEO & Director
• Dr. Robert Benjamin Stein M.D., Ph.D.,
  Exec. VP of R&D
• Peter Martin Carlson CPA,
  Chief Financial Officer
• William F. Hulse IV,
  Gen. Counsel & Sec.
• Scott Turner,
  Senior Vice President - Operations and Procurement
• Dr. Rohit Kashyap Ph.D.,
  Exec. VP & Chief Commercial Officer
• Charles Evans,
  Independent Director
• Neil Yeston,
  Independent Director
• M. Kathleen Behrens Wilsey,
  Independent Chairman of the Board
• James Bierman,
  Independent Director
• K. Todd Newton,
  Independent Director
• Charles Koob,
  Director
• Jack Howarth,
  Senior Vice President of Investor Relations
• Robert Stein,
  Executive Vice President - Research and Development
• Rohit Kashyap,
  Executive Vice President, Chief Commercial Officer
• Martin Sutter,
  Independent Director
• William Hawkins,
  Independent Director
• William Phelan,
  Senior Vice President, Chief Accounting Officer
• William Hulse,
  General Counsel, Secretary
• Mark Graves,
  Chief Compliance Officer
• Scott M. Turner,
  Sr. VP of Operations & Procurement
• Stan Micek,
  Sr. VP of Bus. Devel. & Portfolio Management
• Dr. David H. Mason Jr.,
  Chief Medical Officer
• Hilary Dixon,
  VP of Investor Relations & Corp. Communications
• John J. Howarth,
  Sr. VP of Investor Relations
• William L. Phelan,
  Sr. VP & Chief Accounting Officer
• Larry W Papasan,
  Director
• William Charles Taylor,
  President and COO
• Michael J. Senken,
  Chief Financial Officer
• Joseph G Bleser,
  Director
• Parker H Petit,
  Chairman & CEO
• J Terry Dewberry,
  Director
• Bruce Hack,
  Director
• Luis A Aguilar,
  Director
• Fund 2 Holding Company, L.P...,
  
• Mark Landy,
  EVP & Chief Strategy Officer
• Fund Management Ltd.Okumus ...,
  
• Edward Borkowski,
  EVP & Interim CFO
• Tiffany Olson,
  Director
• Kurt M Eichler,
  Director
• Thomas J Koob,
  Chief Scientific Officer
• Roberta L Mccaw,
  General Counsel and Secretary
• Steve Gorlin,
  Director
• Rebeccah Covert Brown,
  
• Michael J Giuliani,
  Director
• Cato T Laurencin,
  Director
• M Kathleen Behrens,
  Director
• Richard Barry,
  Director
• Joseph H Capper,
  Chief Executive Officer
• Phyllis Gardner,
  Director
• Ricci S Whitlow,
  Chief Operating Officer
• Todd Newton,
  Director
• Rice Doug,
  Chief Financial Officer
• Dorothy E Puhy,
  Director